-
Precigen NASDAQ:PGEN Precigen is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. The Company's technologies enable to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.
Location: 20374 Seneca Meadows Parkway, Maryland, 20876, US | Website: precigen.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
218.3M
Cash
19.54M
Avg Qtr Burn
-17.49M
Short % of Float
13.01%
Insider Ownership
10.18%
Institutional Own.
63.83%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PRGN-2009 OTS AdenoVerse™ +/- Pembrolizumab Details Cancer, Solid tumor/s, Squamous cancers | Phase 2 Update | |
PRGN-2009 AdenoVerse™ + Pembrolizumab Details Cancer, Cervical cancer | Phase 2 Initiation | |
PRGN-2012 AdenoVerse™ Details Recurrent respiratory papillomatosis, Cancer | Phase 1/2 Update | |
PRGN-3005 UltraCAR-T® Details Cancer, Ovarian cancer | Phase 1b Data readout | |
PRGN-3006 UltraCAR-T® Details Cancer, Acute myeloid leukemia | Phase 1b Data readout | |
PRGN-3007 UltraCAR-T® Details Cancer, Blood cancer, Solid tumor/s | Phase 1 Update | |
AG019 ActoBiotics™ Details Type 1 diabetes, Diabetes | Failed Discontinued |